Company Overview
| Stock Name | 華康生物醫學控股有限公司 |
|---|---|
| Stock Code | 08622 |
| Company Full Name | 華康生物醫學控股有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事研發、生產、營銷及銷售體外診斷試劑及輔助生育用品和設備。 |
| Listing Date | 2018-12-13 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港九龍科學館道16號么地道77號華懋廣場10樓1004室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | 開曼群島 |
| Listing Method | 發售以供認購 + 發售以供配售 |
| Listing Board | GEM |
| Website | https://joyzymebiotech.com/ |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 0.50 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 50,000,000 |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 200,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 0.47 |
|---|---|
| First Day Open | HK$ 0.495 |
| First Day Change | -6.00% |
| First Day Volume | 125728000.0 |
| First Day Turnover | 64066800.0 |
Use of Proceeds
| Use of Proceeds | 1、所得款項凈額41.5%（或6.9百萬港元）將用于開發新產品、改良我們的現有產品及開展國際合作項目； 2、所得款項凈額27.3%（或4.5百萬港元）將用于擴展我們的銷售網絡以及加強我們的銷售及營銷活動； 3、所得款項凈額27.9%（或4.6百萬港元）將用于發展輔助生育用品業務； 4、所得款項凈額3.3%（或548,000港元）將用于為營運資金撥付資金。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
RHB Capital Hong Kong Limited CE AGC194
Joint Bookrunners (2)
利得证券(香港)有限公司
EVER-LONG SECURITIES COMPANY LIMITED CE ACM423
Joint Lead Managers (3)
利得证券(香港)有限公司
力高证券有限公司 CE BIE918
Canfield Securities Company Limited CE BIH478
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 張玉靜 |
|---|---|
| Company Secretary | 周麗麒 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 張曙光(34.88%);張賢陽(23.02%) |
|---|
